Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Polypharmacy in fatal clozapine-associated agranulocytosis.

Gerson SL, Lieberman JA, Friedenberg WR, Lee D, Marx JJ Jr, Meltzer H.

Lancet. 1991 Jul 27;338(8761):262-3. No abstract available.

PMID:
1676820
2.

Clozapine-associated agranulocytosis: risk and aetiology.

Krupp P, Barnes P.

Br J Psychiatry Suppl. 1992 May;(17):38-40. Review.

PMID:
1418887
3.

Genetic factors in clozapine-induced agranulocytosis.

Reznik I, Mester R.

Isr Med Assoc J. 2000 Nov;2(11):857-8. Review. No abstract available.

4.

Clozapine: the commitment to patient safety.

Alphs LD, Anand R.

J Clin Psychiatry. 1999;60 Suppl 12:39-42. Review.

5.

Use of cytokines in clozapine-induced agranulocytosis.

Chin-Yee I, Bezchlibnyk-Butler K, Wong L.

Can J Psychiatry. 1996 Jun;41(5):280-4. Review.

PMID:
8793147
6.

[Clozapine-induced agranulocytosis: genetic risk factors and an immunologic explanatory model].

G├╝zelcan Y, Scholte WF.

Tijdschr Psychiatr. 2006;48(4):295-302. Review. Dutch.

7.

Clozapine: balancing safety with superior antipsychotic efficacy.

Meltzer HY.

Clin Schizophr Relat Psychoses. 2012 Oct;6(3):134-44. Review.

PMID:
23006238
8.
9.

Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.

Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J.

J Clin Psychiatry. 1998;59 Suppl 3:3-7. Review.

Supplemental Content

Support Center